Browse IL18BP

Summary
SymbolIL18BP
Nameinterleukin 18 binding protein
Aliases IL18BPa; MC51L-53L-54L homolog gene product; IL-18BP; tadekinig-alfa; Interleukin-18-binding protein
Chromosomal Location11q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted
Domain -
Function

Isoform A binds to IL-18 and inhibits its activity. Functions as an inhibitor of the early TH1 cytokine response.

> Gene Ontology
 
Biological Process GO:0000302 response to reactive oxygen species
GO:0002237 response to molecule of bacterial origin
GO:0002250 adaptive immune response
GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0006979 response to oxidative stress
GO:0010035 response to inorganic substance
GO:0032496 response to lipopolysaccharide
GO:0034599 cellular response to oxidative stress
GO:0034612 response to tumor necrosis factor
GO:0034614 cellular response to reactive oxygen species
GO:0042088 T-helper 1 type immune response
GO:0042542 response to hydrogen peroxide
GO:0070301 cellular response to hydrogen peroxide
GO:0071356 cellular response to tumor necrosis factor
GO:1900115 extracellular regulation of signal transduction
GO:1900116 extracellular negative regulation of signal transduction
Molecular Function GO:0019955 cytokine binding
GO:0030545 receptor regulator activity
GO:0030547 receptor inhibitor activity
GO:0042007 interleukin-18 binding
GO:0048019 receptor antagonist activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-168256: Immune System
R-HSA-449147: Signaling by Interleukins
Summary
SymbolIL18BP
Nameinterleukin 18 binding protein
Aliases IL18BPa; MC51L-53L-54L homolog gene product; IL-18BP; tadekinig-alfa; Interleukin-18-binding protein
Chromosomal Location11q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between IL18BP and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between IL18BP and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
20878981Prostate CarcinomaInhibit immunityIL-18BP was expressed and secreted by the prostate cancer cell lines DU145 and PC3 but not by LNCaP and CWR22, upon interferon-γ (IFN-γ) stimulation. IFN-γ-induced secretion of IL-18BP was enhanced by added TNF-α, IFN-α and IFN-β. The IL-18BP secreted from DU145 and PC3 functionally inhibited IL-18. Immunohistochemical analyses showed positive IL-18BP staining in prostate cancer cells as well as in macrophages in radical prostatectomy specimens. Significant differences in urinary IL-18BP levels (normalized by total protein) collected post-DRE were found between cases with and without cancer on biopsy (p = 0.02) and serum IL-18BP levels correlated with Gleason score (p = 0.03).
23873689Ovarian CancinomaInhibit immunityIn turn, IFN-γ stimulates IL-18-binding protein production, which blocks IL-18 activity. Together, these data indicate that IL-18BP, which is produced in EOC in response to microenvironmental factors, may inhibit endogenous or exogenous IL-18 activity.
Summary
SymbolIL18BP
Nameinterleukin 18 binding protein
Aliases IL18BPa; MC51L-53L-54L homolog gene product; IL-18BP; tadekinig-alfa; Interleukin-18-binding protein
Chromosomal Location11q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of IL18BP in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolIL18BP
Nameinterleukin 18 binding protein
Aliases IL18BPa; MC51L-53L-54L homolog gene product; IL-18BP; tadekinig-alfa; Interleukin-18-binding protein
Chromosomal Location11q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of IL18BP in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1820.714
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.0150.994
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.3270.815
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2250.481
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.1340.93
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.3440.864
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.3680.374
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.6470.576
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.050.969
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 482.0630.232
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.8620.493
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0970.265
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of IL18BP in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.703.70.27
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.703.70.314
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolIL18BP
Nameinterleukin 18 binding protein
Aliases IL18BPa; MC51L-53L-54L homolog gene product; IL-18BP; tadekinig-alfa; Interleukin-18-binding protein
Chromosomal Location11q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of IL18BP. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolIL18BP
Nameinterleukin 18 binding protein
Aliases IL18BPa; MC51L-53L-54L homolog gene product; IL-18BP; tadekinig-alfa; Interleukin-18-binding protein
Chromosomal Location11q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of IL18BP. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by IL18BP.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolIL18BP
Nameinterleukin 18 binding protein
Aliases IL18BPa; MC51L-53L-54L homolog gene product; IL-18BP; tadekinig-alfa; Interleukin-18-binding protein
Chromosomal Location11q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of IL18BP. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolIL18BP
Nameinterleukin 18 binding protein
Aliases IL18BPa; MC51L-53L-54L homolog gene product; IL-18BP; tadekinig-alfa; Interleukin-18-binding protein
Chromosomal Location11q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of IL18BP expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolIL18BP
Nameinterleukin 18 binding protein
Aliases IL18BPa; MC51L-53L-54L homolog gene product; IL-18BP; tadekinig-alfa; Interleukin-18-binding protein
Chromosomal Location11q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between IL18BP and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolIL18BP
Nameinterleukin 18 binding protein
Aliases IL18BPa; MC51L-53L-54L homolog gene product; IL-18BP; tadekinig-alfa; Interleukin-18-binding protein
Chromosomal Location11q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting IL18BP collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.